Innovative early detection with a focus on liquid biopsy and AI

The early detection of pancreatic cancer is developing rapidly: new multimodal approaches combine imaging with molecular biomarkers such as ctDNA, methylation signatures, fragmentomics and proteomics. For high-risk groups in particular, these methods are opening up realistic chances of diagnosis at early, potentially curative stages for the first time. The article provides an overview of current developments and their relevance for Switzerland.